Associations of tumour somatic mutations with cancer-associated venous thromboembolism

BackgroundVenous thromboembolism (VTE) is a common complication of cancer. Complex interactions between tumour biology and the haemostatic system may contribute to development of cancer-associated VTE. ObjectivesThis study examined associations of somatic mutations with VTE in a large multi-cancer cohort. MethodsWe analysed paired tumour and germline whole genome sequence data and electronic health records from 12,507 cancer patients recruited to the Genomics England National Genomic Research Library, to evaluate associations of somatic mutations across 608 genes, overall tumour mutational burden (TMB) and 25 single base substitution (SBS) mutational signatures with VTE. Interactions between somatic mutations and a germline polygenic risk score for VTE were also assessed. ResultsIn multivariable Cox regressions adjusted for age, sex and genetic ancestry, somatic mutations in four genes associated with higher rates of VTE at a false-discovery rate <0.1: CDKN2A (Hazard ratio, HR=1.62 [95% confidence interval, 1.23-2.13]), KRAS (HR=1.31 [1.12-1.53]), PCDH15 (HR=1.48 [1.24-1.76]) and TP53 (HR=1.55 [1.38-1.73]). SBS8, a common mutation signature of unknown aetiology, was also associated with higher rates of VTE (HR=1.39 [1.16-1.66]). In contrast, TMB [≥]20 mutations/Mb, two DNA mismatch repair signatures (SBS6 and SBS26) and one rare signature of unknown aetiology (SBS19) associated with lower rates of VTE. Evidence for these associations remained robust after additional adjustment for tumour type, stage, and systemic anti-cancer treatment. ConclusionsThese findings support the hypothesis that tumour somatic mutations influence risk of VTE. This may provide insights into the pathophysiology of cancer-associated VTE and inform future efforts to improve clinical risk prediction.